Study supports use of LMWH over warfarin for treatment of acute VTE in patients with active cancer

the ONA take:

The use of the low molecular-weight heparin (LMWH) tinzaparin daily for 6 months compared with warfarin was associated with a lower rate of clinically relevant nonmajor bleeding among patients with active cancer and acute symptomatic venous thromboembolism (VTE), according to a new study published in JAMA; however, there was no significant difference in reducing recurrent VTE, overall death, or major bleeding.

Previous data has shown that LMWH is preferred over warfarin for the treatment of acute VTE in patients with active cancer, but that recommendation is largely based on results of a single trial. Therefore, researchers sought to compare the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic VTE in patients with active cancer.

For the study, researchers enrolled 900 adult patients with active cancer from 164 centers in 5 continents and randomly assigned them 1:1 to receive tinzaparin 175 IU/kg once daily for 6 months vs conventional therapy with tinzaparin 175 IU/kg once daily for 5 to 10 days followed by warfarin dose-adjusted to an INR of 2.0-3.0 for 6 months.

The findings suggest that further studies are warranted to evaluate efficacy outcomes among patients with active cancer at higher risk for recurrent VTE.

Study supports use of LMWH over warfarin for treatment of acute VTE in patients with active cancer
Use of low molecular-weight heparin (LMWH) tinzaparin daily associated with lower rate of bleeding among patients with active cancer.
Among patients with active cancer and acute symptomatic VTE, the use of the LMWH tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs